Arran Attridge

Bio:

Arran Attridge most recently served as Senior Vice President of Corporate Communications for Vir Biotechnology where she led communications, patient advocacy and stakeholder engagement. Attridge now serves as a strategic communications advisor to emerging biotech CEOs and leadership teams as they navigate key business opportunities and inflection points. Her work helps build positive reputation and trust across key stakeholders to support long-term business strategy. She has more than two decades of experience as a public relations and advocacy leader, guiding communications strategy through pre-clinical and clinical development, regulatory review, launch and in-market access across a range of therapeutic areas.

Previously Attridge served as Vice President at CymaBay Therapeutics which was acquired by Gilead Sciences for $4.3bn. There she led corporate communications in preparation for commercialization and through the acquisition of the company. Prior to that, Attridge served over a decade at Gilead Sciences where she held roles of increasing responsibility in the U.S. and Europe. During her tenure she led communications across HIV, viral hepatitis (B, C and delta), COVID-19, liver diseases, inflammation, emerging viruses and cancers. She served for over nine years as a public relations consultant to the pharmaceutical industry with a focus on corporate reputation, advocacy and product commercialization.

Attridge completed her Bachelor of Science degree in genetics from the University of York in the U.K. and holds a professional certificate from the U.K. Chartered Institute of Marketing.